August 25, 2021
Meiji Seika Pharma said on August 24 that its phosphodiesterase 4 (PDE4) inhibitor ME3183 has been shown to be safe and well tolerated in a PI clinical trial conducted in the US with healthy volunteers. The company plans to initiate...read more